What are umbilical cord MSCs?
Umbilical cord MSCs, or UC-MSCs, are mesenchymal stem cells isolated from donated umbilical cord tissue after a healthy full-term birth. The cord is normally discarded, so collecting it carries no risk to mother or baby, and a single screened donation can be expanded in the laboratory into many banked treatment doses.
Cord tissue is one of the three main MSC sources, alongside bone marrow and fat, and it has become the workhorse of stem cell therapy around the world for practical reasons: the cells come from the youngest tissue available, they expand readily in culture, and they can be prepared, tested, and frozen ahead of time, sitting ready off the shelf when a patient needs them. No bone marrow draw, no liposuction, no procedure on the patient at all.
How do they work?
Like all MSCs, cord cells are understood to work by signaling rather than by becoming new tissue. When they arrive in inflamed or injured tissue, they release growth factors, anti-inflammatory signals, and membrane vesicles that quiet an overactive immune response and recruit the body's own repair machinery. The full story of that mechanism, and what decides whether any MSC treatment works, is in our MSC therapy explainer.
What makes the cord version distinct is less the mechanism than the practicalities: who the cells come from, and how the product reaches the clinic.
Why cord cells matter in regenerative medicine
The first advantage is the donor. With bone marrow or fat, the patient is usually also the donor, so the cells are as old and as metabolically stressed as the person they came from. Cord cells come instead from a screened, healthy, full-term birth, and one good donation becomes a consistent bank of doses.
The second advantage is what happens at the immune level. In every randomized trial discussed below, unrelated recipients received cord cells with no donor matching and no anti-rejection drugs, something unthinkable with an organ transplant. MSCs display little of what the immune system uses to spot foreign tissue, which is why they can be given off the shelf. The record is not perfectly silent on this: in one early pediatric study, five of twelve children developed antibodies against donor markers after repeated doses, with no clinical consequence so far. Honest reading: cord cells are low-immunogenicity, not invisible, and the question matters most for repeat courses.
How the products are made
There is no such thing as a same-day cord cell treatment. Cord tissue is processed and cryopreserved after collection, and the cells must be culture-expanded over weeks in the laboratory before they amount to a dose at all. That lab time is where quality is won or lost, and it is why two products both called "umbilical cord stem cells" can be very different medicines.
A properly made product comes from a screened donor, is expanded under controlled conditions, is tested for identity and potency, and is frozen with a defined process. Because every clinical dose is thawed from frozen, serious manufacturers run post-thaw viability testing, which verifies how many cells are alive and functional in the dose the patient actually receives. Donor and lot differences are one of the main reasons trial results vary, so these are numbers worth asking any provider for, not paperwork trivia.
What they are used for
Start with the honest regulatory picture: no umbilical cord MSC product is approved by the FDA or EMA for any use. The one MSC product approved in the United States, for children with steroid-refractory graft-versus-host disease, is made from bone marrow. So the regulatory bar has been cleared by this cell type once, from a different tissue source.
The research activity, though, concentrates on cord cells. More than forty randomized trials of intravenous or intra-arterial UC-MSCs have been completed in adults, across graft-versus-host disease, type 2 diabetes, COVID-19 lung injury, heart failure, knee osteoarthritis, aging frailty, and stroke, with autism studied in children. Beyond the trials, cord-derived cells are the standard offering in regenerative clinics around the world, used under physician direction in jurisdictions that permit it.
Strong Craft Regen coordinates physician-led treatment through Dr. Adas Darinskas and the team at Innovita Clinic in Vilnius, with protocols adjusted to the individual client rather than run identically for everyone.
What clients notice in practice
What we hear from clients after cord cell treatment, labeled honestly as experience rather than trial evidence, tends to be gradual: steadier energy and recovery over the following weeks, joints that loosen and quiet down, inflammatory symptoms that settle for a stretch. Some people report a lot, some report little, and that spread matches the science: the product, the dose, the schedule, and the person receiving it all vary.
The same honest gap we describe in the MSC explainer applies here. People who do well rarely go get the follow-up scans and bloodwork that would document it, and almost nobody publishes their case, so the strongest experiences stay anecdotal while the trial record stays thin. We would rather name that than pretend either half of the picture is the whole of it.
The pros and the cons
What's promising
- Off-the-shelf availability from screened donors, with no harvesting procedure on the patient.
- A reassuring randomized safety record: across 42 trials and 2,280 adults, short-lived fever was the only adverse-event signal.
- Primary endpoints met in randomized trials in type 2 diabetes, and pooled COVID-19 pneumonia data favored the cells on survival.
- In the knee, two doses six months apart beat both a single dose and hyaluronic acid on pain.
What's uncertain
- No cord MSC product holds FDA or EMA approval; every use is investigational.
- The two most tightly controlled trials, in graft-versus-host disease and autism, did not beat their comparators on their primary endpoints.
- Most trials are small and single-center, and no large multicenter trial has yet repeated a winning regimen at scale.
- Donor and lot variability is real, and potency testing is not standardized across manufacturers.
Worth considering
- Ask for the manufacturing numbers: donor screening, potency testing, and post-thaw viability.
- Repeat courses raise the antibody question from the pediatric study; worth discussing with the physician.
- Twelve months is the longest routine follow-up in the randomized record so far.
- This is a physician-level decision, made on your history and goals, not a menu order.
Why the evidence lags the practice
Cells expanded from donated tissue are hard to patent, and late-stage trials get funded when someone owns a product that can repay them. So the cord-cell record is a collection of small, hospital- and university-funded trials rather than the large multicenter programs that settle questions. What the field lacks is not signals but scale: a big trial repeating a regimen that worked in a small one.
Keep the two kinds of unknown separate. A trial that ran and found no advantage is a result about the regimen it tested. Where no trial has run, there is no result to read: sepsis, for example, has 26 supportive animal studies and no reported human trial. Untested is not the same as tested and found wanting, in either direction.
What the key trials tested
Our framing rule for evidence: a trial tests one product, at one dose, by one route, on one schedule, against one comparator. First, where the cord-cell evidence sits:
Preclinical & practice
Sepsis (animal data only), plus most recovery and longevity uses offered in clinics.
Early trials
Heart failure, aging frailty, stroke, knee osteoarthritis.
Late-stage trials
Graft-versus-host disease, autism, type 2 diabetes, COVID-19 pneumonia.
Approved uses
None yet for cord products. The US-approved MSC product is bone-marrow derived.
And the trials that matter most:
- In graft-versus-host disease, 78 patients all received an active second-line drug, and half also got eight infusions of cord cells. Response at day 28 was 60% versus 50%, not a statistically significant advantage. A higher dose, a longer course, and cells on their own were not tested.
- In autism, the 137-child Duke trial gave one intravenous infusion against placebo and found no advantage on its six-month endpoint. Repeat dosing, which the earlier open-label study used, has never been tested under control.
- In type 2 diabetes, three infusions four weeks apart met the primary endpoint at 48 weeks: 20% of treated patients reached the glucose-control target versus 4.55% on placebo.
- In COVID-19 lung failure, a 24-patient double-blind trial found 91% survival with two infusions versus 42% with placebo, and seven pooled trials point the same direction on mortality.
- In the knee, two doses of 20 million cells six months apart beat both a single dose and hyaluronic acid on pain at 12 months, with no change on MRI.
- In heart failure, a single-infusion trial saw ejection fraction improve while a three-infusion trial did not. The schedules have never been compared head to head, and schedule is one of the biggest untested variables in this whole field.
Every study behind this article, plus the rest of our research library, is filterable on our Science page.
Questions people ask
Are umbilical cord stem cells approved?
No cord MSC product is approved by the FDA or EMA for any use; cord cells are investigational everywhere they are studied. The one US-approved MSC product, for steroid-refractory graft-versus-host disease in children, is made from bone marrow. Cord-cell treatment is offered under physician direction in jurisdictions that permit it, with no guaranteed outcome.
Does the donor need to match me?
No. In every randomized trial discussed here, unrelated recipients received cord cells without donor matching and without anti-rejection drugs, because MSCs show little of what the immune system uses to spot foreign tissue. The record is not perfectly silent: in one early pediatric study, some children developed antibodies against donor markers after repeat doses, with no clinical consequence so far. It is a fair question to raise before a repeat course.
How are cord cell products made?
Cord tissue is donated after a healthy full-term birth, with the donor screened. The cells are isolated, culture-expanded in the laboratory over weeks into full treatment doses, tested, and cryopreserved under controlled conditions. A properly made product comes with identity, potency, and post-thaw viability testing, which verifies how many cells are alive and functional once a dose is thawed for treatment.
Are umbilical cord MSCs safe?
A 2026 systematic review pooled 42 randomized trials of intravascular cord MSCs in 2,280 adults and found one adverse-event signal: short-lived fever. Infection, death, malignancy, and clotting events showed no signal, and no trial stopped early for safety. The placebo-controlled pediatric trial followed 137 children for a year with one serious adverse event in each arm. Twelve months is the longest routine follow-up, and safety in any individual case depends on the product and the provider.
What to take away
If you remember five things from this article, make them these:
- Cord MSCs are donated-at-birth cells expanded into off-the-shelf doses: the most practical MSC source, and the one most clinics worldwide actually use.
- They are given to unrelated recipients without donor matching, and the randomized safety record across 2,280 adults is reassuring, with short-lived fever the one consistent signal.
- No cord product is FDA or EMA approved yet, and results differ by condition and regimen: endpoints met in diabetes and pooled COVID data, not in the strictest trials in graft-versus-host disease and autism.
- Quality lives in the manufacturing: donor screening, culture expansion, potency testing, and the post-thaw viability numbers a serious maker can show you.
- Treatment decisions belong with a qualified physician, with expectations set by what has been tested for the condition and regimen in question.
The evidence
Selected references, each verified against primary sources (PubMed, ClinicalTrials.gov and DailyMed). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Umbilical Cord MSCs is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.